Our data demonstrate that DCs are crucial determinants of tumor immunogenicity; upon DC boost treatment, there is an infiltrate of activated DCs and CD4+ and CD8+ T cells in the tumors, whereas the migratory skin DCs, and especially the dermal cDC1 and cDC2, acquire the ability to prime CD8+ T cell responses in the tumor-draining LN. The gene discussed is CD8A; the disease is neoplasm.